Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.68 |
| ▸ | F2 | P00734 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761205 | 0.90 | F10 (0.66) | F10F2ABCB11ST14 | |
| SCHEMBL4761157 | 0.89 | F10 (0.66) | F10F2ABCB11ST14 | |
| SCHEMBL13232191 | 0.88 | F10 (0.69) | F10F2ABCB11ST14 | |
| SCHEMBL4761201 | 0.87 | F10 (0.67) | F10F2ABCB11ST14 | |
| SCHEMBL4751599 | 0.87 | F10 (0.69) | F10F2ABCB11ST14 | |
| SCHEMBL4761182 | 0.86 | F10 (0.74) | F10F2ABCB11ST14 | |
| SCHEMBL19338363 | 0.86 | F10 (0.56) | F10 | |
| SCHEMBL4761185 | 0.85 | F10 (0.71) | F10F2ABCB11ST14 | |
| SCHEMBL4761160 | 0.83 | F10 (0.68) | F10F2ABCB11ST14 | |
| SCHEMBL4761210 | 0.83 | F10 (0.71) | F10F2ABCB11ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307407-B1 | FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD (KR) | 2016-03-16 | — | — | EP | disclosed |
| US-8637667-B2 | Method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives | LEGOCHEM BIOSCIENCE LTD. (KR) | 2014-01-28 | — | — | US | disclosed |
| US-8178525-B2 | FXA inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-8178525-B2 | FXA inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-20120108808-A1 | METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-05-03 | — | — | US | disclosed |
| US-20110112083-A1 | FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112083-A1 | FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| WO-2011005028-A2 | METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES | LEGOCHEM BIOSCIENCE LTD. (KR) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010002115-A2 | FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112083-A1 | FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | F12, F2, F11 | F10 6/4885F2 2/4885ABCB11 3311/4885 |
| US-20120108808-A1 | METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES | F2, F11, F5 | F10 15/4885F2 1/4885ABCB11 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.